LB Pharmaceuticals Inc (LBRX): R&D Expense
$16.74M
Year ended 2025-12-31
$69.69M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.74M | -67.3% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $51.17M | n/a | 2026-03-26, From 2024-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| LB Pharmaceuticals Inc (LBRX) | 2025-12-31 | $16.74M | -67.3% |
| Atea Pharmaceuticals, Inc. (AVIR) | 2025-12-31 | $148.02M | +2.7% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $104.00M | -5.1% |
| Omeros Corp (OMER) | 2025-12-31 | $81.30M | -32.0% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $60.26M | +5.2% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $134.85M | -39.4% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $13.18M | -32.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $39.28M | -17.9% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $58.03M | +28.7% |
Compare LBRX, AVIR, ADCT, OMER side by side · Screen every company in Pharmaceutical Preparations ↗